Skip to main content
Premium Trial:

Request an Annual Quote

PTC Therapeutics Takes $35M Series E

NEW YORK, Jan. 7 (GenomeWeb News) -- PTC Therapeutics of South Plainfield, NJ, announced today the closing of a $35 million Series E round of funding led by CSFB Private Equity and HBM Bioventures.

 

Additional investors included Bay City Capital, Delphi Ventures, Hansa Special Opportunities Fund Ltd., HealthCap, Novartis BioVentures, Novo A/S, POSCO BioVentures and Vulcan Capital.

 

The six-year-old company, which focuses on RNA biology, particularly gene-expression modulation by small molecules, has raised $91 million in venture capital funding. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.